Surgical Robotics’ Real Edge in 2026 Is Knowing When Not to Launch

CMR Surgical spent the past year doing the one thing most venture-backed hardware companies cannot bring themselves to do. It held its US launch. CEO Massimiliano Colella, who took over in late 2024, stopped the planned rollout of the original Versius robot and waited roughly a year for the second-generation Versius Plus, telling MedTech Dive he did not want to launch the first generation into the US market. CMR has raised close to $1.5 billion, the most of any surgical device startup, and Versius is the second most-adopted soft-tissue robot outside the US, with more than 40,000 procedures across 30-plus countries since its 2019 CE mark. The decision to wait is the story. In a year when Medtronic, Johnson & Johnson, and a field of smaller challengers are all moving on Intuitive Surgical’s lead, the companies pulling ahead are the ones treating launch timing and launch position as design decisions, not as the reflex of shipping whatever is ready the day the round closes.

Waiting a Year for the Right Generation Is a Sequencing Decision, Not a Delay

Versius Plus received FDA clearance in December 2024 for gallbladder removal, with further submissions across gastrointestinal, gynecology, urology, and general surgery indications working through the agency during 2026, per MedTech Dive. CMR is running a soft US launch, partnering selectively with hospitals and surgery centers before any broad rollout. Colella has been blunt about why: the market does not forgive a single mistake. If you are building a surgical robotics or interventional device platform, the gravitational pull is always toward launching the generation you have, because the early revenue clock and the reference-site flywheel both start the moment the first system goes live. CMR’s read was that the first commercial impression in a market this unforgiving is worth more than the months of early revenue a generation-one launch would have bought. Which generation earns your first reference site is one of the highest-leverage calls a hardware CEO makes, and it is almost never the one the cap table wants you to make.

The Challengers Are Competing Where the Incumbent Cannot Go Cheaply

The smaller entrants are not trying to out-da-Vinci the da Vinci. Distalmotion and Moon Surgical are aiming squarely at ambulatory surgery centers, with Virtual Incision and CMR also pursuing outpatient-focused facilities, per MedTech Dive. Versius is portable and modular, designed to move between operating rooms, and Colella has framed it as complementary to whatever a hospital already runs rather than as a rip-and-replace. That is the right instinct against a 20-year incumbent, and it generalizes well past surgical robotics. A founder facing an entrenched leader, whether that is Intuitive in soft-tissue surgery, a defense prime in autonomy, or an established name in industrial automation, rarely wins with a feature-for-feature assault on the incumbent’s home turf. The opening is the segment the leader’s product architecture cannot serve economically. ASCs are exactly that kind of structural gap, because the capital cost and physical footprint of the dominant system were never designed to fit an outpatient setting.

Medtronic and J&J Are Entering on Very Different Clocks

The two best-capitalized entrants are pacing themselves years apart. Medtronic’s Hugo system cleared in urology in December 2024 and the company is now pursuing general surgery and gynecology, with expected early uptake among loyal Medtronic accounts and surgeons not already on Intuitive systems, per MedTech Dive. Johnson & Johnson submitted an FDA De Novo request for its Ottava robot on January 7, 2026, targeting general surgery procedures in the upper abdomen including gastric bypass and sleeve, backed by an investigational device exemption study in Roux-en-Y gastric bypass. Neither is launching broad. Both are sequencing one indication at a time. For a founder watching deep-pocketed competitors crowd into the category, the read is that capital does not collapse the timeline. Regulatory and clinical evidence still gate each indication individually, and a balance sheet the size of Medtronic’s or J&J’s buys reach, not the ability to skip the queue.

Intuitive’s Answer Is Cadence, and the Read-Across Is General

The incumbent is defending with release velocity. Intuitive has added video replay, tissue-force measurement, and new instruments to the da Vinci platform, and in January 2026 it secured FDA clearance for nine new cardiac indications including mitral and tricuspid valve repair, per MedTech Dive. The company forecasts 13 to 15 percent worldwide da Vinci procedure growth for 2026, down from 18 percent the prior year, and analysts put the point where competition meaningfully bites two to three years out. Cadence on a large installed base is the same moat playbook a climate-hardware or industrial-robotics founder will eventually face from an entrenched leader. You do not beat it by matching the release schedule. You beat it by owning a position the leader’s roadmap does not prioritize, which is precisely why the cardiac and ASC openings exist at all. Even a 20-year leader cannot be everywhere first, and the gap between where it is and where it is going next is where a challenger gets to build.

Dave Saunders is the founder of Base Reality Group and a Fractional CPO for hard-tech founders. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →